Applied BioCode Stock

Applied BioCode Intangible Assets

Intangible Assets of Applied BioCode (6598.TW) as of Sep 3, 2026.

Intangible Assets

0.00TWD

Last updated:

Intangible Assets of Applied BioCode is 2026 0.00 TWD. Intangible Assets of Applied BioCode was 2025 1.80 M TWD. It decreases by % lower compared to the previous year.

The Applied BioCode Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2018
26.68 M TWD
Jan 1, 2019
21.97 M TWD
Jan 1, 2020
17.20 M TWD
Jan 1, 2021
13.43 M TWD
Jan 1, 2022
10.38 M TWD
Jan 1, 2023
6.02 M TWD
Jan 1, 2024
1.80 M TWD
Jan 1, 2025
0.00 TWD
The Applied BioCode Intangible Assets history
YEARIntangible AssetsYoY
0.00TWD-100.00%
1.80 MTWD-70.11%
6.02 MTWD-42.00%
10.38 MTWD-22.75%
13.43 MTWD-21.88%
17.20 MTWD-21.74%
21.97 MTWD-17.63%
26.68 MTWD+16.28%
22.94 MTWD-18.78%
28.25 MTWD
0.00TWD
0.00TWD
0.00TWD
0.00TWD
Access this data via the Eulerpool API

Applied BioCode Stock analysis

What does Applied BioCode do? Applied BioCode Corp is a California-based company that focuses on the development and marketing of diagnostic instruments and tests. The company was founded in 2004 by an experienced management team and has since developed a number of groundbreaking technologies to improve the diagnosis of diseases such as cancer, infectious diseases, and autoimmune diseases. The business model of Applied BioCode Corp is based on the development of innovative diagnostic instruments and test systems based on proprietary technologies. The company has a strong partnership with a leading manufacturer of diagnostic automation systems, allowing a wide range of tests for various diseases to be offered. Applied BioCode Corp also works closely with leading research and development organizations to leverage the latest insights in the field of diagnostics. One of the divisions of Applied BioCode is molecular diagnostics, which is an essential component of modern medicine. Molecular diagnostics enables the detection of genetic changes and deviations related to diseases. Applied BioCode's technology allows for rapid and precise identification of pathogens in clinical samples such as blood, urine, and tissue samples. Another important area for Applied BioCode is infectious disease diagnostics. The company has developed a range of test systems based on a variety of infectious diseases such as influenza, tuberculosis, and sexually transmitted diseases such as chlamydia and gonorrhea. These tests can be performed individually or as a group to facilitate disease diagnosis and improve treatment. Applied BioCode also offers tests for the detection of oncological markers. These tests are crucial for the early detection of cancer and monitoring the treatment of cancer patients. Applied BioCode's technology enables rapid and precise identification of cancer cells in blood or tissue, which can improve the effectiveness of treatment. Another important product of Applied BioCode is the BioCode Analyzer, an automated diagnostic instrument. The BioCode Analyzer is a high-throughput system capable of performing multiple tests simultaneously. The analyzer is equipped with a disposable chip that allows for quick and easy diagnosis. This makes the BioCode Analyzer a powerful tool for laboratory automation, providing fast and accurate diagnosis for a variety of diseases. Applied BioCode is also dedicated to researching and developing new technologies. The company has an active pipeline of new products and technologies to further improve diagnostic accuracy and the number of feasible tests. Applied BioCode is also developing new applications for its technologies to improve the diagnosis and treatment of diseases in various ways. In summary, Applied BioCode Corp plays an important role in the field of diagnostic technology. The company has developed a wide range of innovative diagnostic tests and instruments that enable diseases to be quickly and accurately detected. With its strong partnership with leading diagnostic automation system manufacturers and research organizations, Applied BioCode will continue to stay at the forefront and improve diagnostic practice. Applied BioCode is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Applied BioCode stock

On Eulerpool you can find the complete historical development of Intangible Assets Applied BioCode since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Applied BioCode historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Applied BioCode

All Key Metrics — Applied BioCode